Long-term comparison of a calcium-free phosphate binder and calcium carbonate - Phosphorus metabolism and cardiovascular calcification

Clinical Nephrology

Volumn 62, Issue 2, 2004, Pages 104-115

  Braun, J ^a   Asmus, H G ^b   Holzer, H ^c   Brunkhorst, R ^d   Krause, R ^b   Schulz, W ^e   Neumayer, H H ^b,f   Raggi, P ^g   Bommer, Juergen ^h  

^a KfH Dialyzezeritrum Nurnberg   (Germany)

^b KfH Dialysezentrum   (Germany)

^c UNIVERSITY HOSPITAL GRAZ   (Austria)

^d KfH Dialysezentrum   (Germany)

^e KLINIKUM BAMBERG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g TULANE UNIVERSITY   (United States)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Calcification; Calcium; Hyperparathyroidism; Phosphate; Sevelamer

Indexed keywords

CALCIUM; CALCIUM CARBONATE; CARBON DIOXIDE; CHLORIDE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SERTURNER; SEVELAMER;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; HYPERCHLOREMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SAFETY;

EID: 4444227474     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp62104     Document Type: Article

References (35)

1. Achenbach S, Ropers D, Mohlenkamp S 2001 Variability of repeated coronary artery calcium measurements by electron beam tomography. Am J Cardiol 87: 210-213
2. Agatston AS, Janowitz WR, Hildner FJ 1990a Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15: 827-832
3. Agatston AS, Janowitz WR, Hildner FJ 1990b Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15: 827-832
4. Alfrey AC 1993 Aluminum toxicity in patients with chronic renal failure. Ther Drug Monit 15: 593-597
5. Amend JC, Steinberg SM, Lowrie EG, Lazarus JM 1975 The influence of serum calcium and parathyroid hormone upon glucose metabolism in uremia. Lab Clin Med 86: 435-444
6. Becker BN, Himmelfarb J, Henrich WL, Hakim RM 1997 Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other nontraditional risk factors. J Am Soc Nephrol 8: 475-486
7. Blake GJ, Otvos JD 2002 Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106: 1930-1937
8. Bleyer AJ, Burke SK, Dillon M, Garrett B 1999 A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: 694-701
9. Block GA, Port FK 2000 Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35: 1226-1237
10. Block GA, Hulbert-Shearon TE, Levin NW, Port FK 1998 Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 601-617
11. Bostom AG, Lathrop L 1997 Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 52: 10-20
12. Braun J, Oldendorf M, Moshage W 1996 Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394-401
13. Callister TQ, Raggi P, Cooil B 1998 Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339: 1972-1978
14. Callister TQ, Cooil B, Raya SP 1998 Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology 208: 807-814
15. Chertow GM, Burke SK, Raggi P 2002 Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252
16. Chertow GM, Burke SK, Dillon MA, Slatopolsky E 1999 Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14: 2907-2914
17. Chertow GM, Dillon MA, Amin N, Burke SK 2000 Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. J Ren Nutr 10: 125-132
18. Foley RN, Parfrey PS, Sarnak MJ 1998 Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (5 Suppl 3): S112-119
19. Friedewald W, Levy R, Fredrickson D 1972 Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clin Chem 18: 499-502
20. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK 2001 Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138
21. Garg A, Grundy S 1994 Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: a short term double-blind crossover trial. Ann Intern Med 121: 416-422
22. Goodman WG, Goldin J, Kuizon BD 2000 Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483
23. Guérin AP, Blacher J, Pannier B 2001 Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103: 987-992
24. Guérin AP, London GM, Marchais SJ, Metvier F 2000 Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021
25. Hergesell O, Ritz E 2002 Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant 17: 14-17
26. Mak RHK 1992 Intravenous 1,25-dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 41: 1049-1054
27. Nishizawa Y, Shoji T, Kawagishi T, Morii H 1997 Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int 62 (Suppl): S90-S92
28. Oda H, Keane WF 1998 Lipid abnormalities in end-stage renal disease. Nephrol Dial Transplant 13: 45-49
29. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P 2002 Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106: 100-105
30. Raggi P, Boulay A, Chasan-Taber S 2002 Cardiac calcification in adult hemodialysis patients: a link between ESRD and cardiovascular disease? J Am Coll Cardiol 39: 695-701
31. Rumberger JA, Brundage BH, Rader DJ, Kondos G 1999 Electron beam computed tomographic coronary calcium scanning: a review of guidelines on use in asymptomatic persons. Mayo Clin Proc 74: 243-252
32. Slatopolsky EA, Burke SK, Dillon MA 1999 Renagel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The Renagel Study Group. Kidney Int 55: 299-307
33. Tamashiro M, Iseki K, Sunagawa O 2001 Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 38: 64-69
34. Tsuchihashi K, Takizawa H, Torii T, Ikeda R, Nakahara N, Yuda S, Kobayashi N, Nakata T, Ura N, Shimamoto K 2000 Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D(3) analog administration in dialysis patients with end-stage renal disease. Nephron 84: 13-20
35. US Renal Data System USRDS 2000 Annual Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD